ARX Shares Aroa Biosurgery Limited
ASX · ASXLast in our picks 2026-10-26 — not in the current list; analysis below is from that screen
Wound-care technology expansion offers asymmetric growth potential from a low valuation base.
Future value: $1.08 (+105.77%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Bell Potter reiterated Buy with doubled target potential.
- ▾Below 50-day MA (-1.65%)
- ▸~106% upside to price target
Is ARX a buy right now?
Trend: ARX is trading above the 50-day average (+0.00%), RSI 39 — neutral momentum, with a 3-month return of -6.19%.
Valuation & quality: Aroa Biosurgery Limited trades on a trailing P/E of 53.0, forward P/E 18.1, price-to-book 2.27; fundamentals show net margin 4.5%, return on equity 4.9%, revenue growth 29.5% year on year.
Analyst consensus: 3 analysts have a mean 12-month price target of A$1.08 (+104% vs the last close; range A$0.79 – A$1.36), consensus rating “none”.
Our screen: BUY (score 3) — Wound-care technology expansion offers asymmetric growth potential from a low valuation base.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -11.90% | +6.80% | +9.50% | -13.00% | -5.00% | -1.80% | -7.10% | +1.90% |
Fundamentals
Analyst price target
Technical signals
About Aroa Biosurgery Limited
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.
Sector: Healthcare · Industry: Medical Devices · New Zealand · Website
Related Health Care picks
Browse: all ASX stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.